Novolog and Dysgraphia - a phase IV clinical study of FDA data

Summary:

Dysgraphia is reported as a side effect among people who take Novolog (insulin aspart recombinant), especially for people who are female, 60+ old, also take Lantus, and have Pain.

The phase IV clinical study analyzes which people have Dysgraphia when taking Novolog. It is created by eHealthMe based on reports of 55,653 people who have side effects when taking Novolog from the FDA, and is updated regularly.

What is Novolog?

Novolog has active ingredients of insulin aspart recombinant. It is often used in diabetes. eHealthMe is studying from 56,160 Novolog users. Check the latest studies of Novolog.

What is Dysgraphia?

Dysgraphia (impaired ability to learn to write) is found to be associated with 551 drugs and 652 conditions by eHealthMe. Check the latest studies of Dysgraphia.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 04, 2026

55,653 people reported to have side effects when taking Novolog.
Among them, 23 people (0.04%) have Dysgraphia.

Among these 23 people:

What is the gender of people who have Dysgraphia when taking Novolog? *

female: 72.73 %
male: 27.27 %

What is the age of people who have Dysgraphia when taking Novolog? *

What are other drugs people take besides Novolog? *

What are other side effects people have besides Dysgraphia? *

Memory Loss: 11 people, 47.83%
Stroke (sudden death of a portion of the brain cells due to a lack of oxygen): 9 people, 39.13%
Tremor (trembling or shaking movements in one or more parts of your body): 8 people, 34.78%
Neuropathy Peripheral (surface nerve damage): 8 people, 34.78%
Haemorrhage (bleeding): 5 people, 21.74%
Weakness: 5 people, 21.74%
Hypoaesthesia (reduced sense of touch or sensation): 5 people, 21.74%
Infection: 4 people, 17.39%
Pain In Extremity: 4 people, 17.39%
Ill-Defined Disorder: 4 people, 17.39%

What are the existing conditions these people have? *

Pain: 7 people, 30.43%
Cardiac Disorder: 4 people, 17.39%
Cardiac Ventricular Thrombosis (blood clot in ventricle): 4 people, 17.39%
Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 4 people, 17.39%
Depression: 4 people, 17.39%
Diabetic Neuropathy (neuropathic disorders that are associated with diabetes mellitus): 4 people, 17.39%
High Blood Pressure: 3 people, 13.04%
Chest Pain: 2 people, 8.70%
Neuropathy Peripheral (surface nerve damage): 2 people, 8.70%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 2 people, 8.70%

* Approximation only. Some reports may have incomplete information.

Do you take Novolog and have Dysgraphia?

- Check whether Dysgraphia is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Novolog:

Novolog (56,160 reports)

Dysgraphia treatments and more:

Dysgraphia (7,998 reports)

Browse all side effects of Novolog:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Dysgraphia:

Dysgraphia (551 drugs)

Browse all the conditions that are associated with Dysgraphia:

Dysgraphia (652 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on insulin aspart recombinant (the active ingredients of Novolog) and Novolog (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.